Can a simple test predict immunotherapy success in head and neck cancer?
NCT ID NCT05328024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting blood and tumor samples from 60 people with recurrent or metastatic head and neck cancer who are receiving standard anti-PD1 immunotherapy. The goal is to find biological markers that can predict whether the immunotherapy will work. Researchers will analyze the samples to see if certain genetic signatures are linked to better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-PD1 immunotherapy
What this could lead to
If successful, this could help doctors predict which patients will benefit from anti-PD1 immunotherapy, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not identify reliable biomarkers, and results may not change current practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut de cancérologie Strasbourg Europe
RECRUITINGStrasbourg, France, 67033, France
Contact
Contact